Table of Content

1. Introduction to Trispecific Antibody
1.1 Overview
1.2 Historical Perspective


2. Trispecific Antibody Mechanism of Action


3. Trispecific Antibodies vs. Other Cancer Therapies
3.1 Trispecific Antibodies vs. Monoclonal Antibodies
3.2 Trispecific Antibody vs. Bispecific Antibody
3.3 Trispecific Antibodies vs. Gene & Cell Therapy
3.4 Trispecific Antibody vs. Peptide Based Drugs
3.5 Trispecific Antibody vs. Conventional Cancer Therapies


4. Role of Trispecific Antibodies in Cancer
4.1 Overview
4.2 Therapeutic Target for Trispecific Antibodies in Cancer


5. Role of Trispecific Antibodies in Multiple Filovirus


6. Role of Trispecific Antibodies in HIV
6.1 Overview
6.2 Therapeutic Targets for Trispecific Antibodies in HIV


7. Global Trispecific Antibody Market Outlook


8. Global Trispecific Antibody Market Analysis
8.1 Current Market Scenario
8.2 Future Market Opportunity


9. Trispecific Antibody Ongoing Research & Development
9.1 GTB3550
9.2 NM21 -1480
9.3 HPN424
9.4 SAR443216


10. Upcoming Trispecific Antibodies Sales Assessment 2028


11. Trispecific Antibodies Clinical Trials Insight
11.1 By Phase
11.2 By Development Status
11.3 By Region
11.4 By Indication


12. Global Trispecific Antibodies Clinical Trials Insight 2028
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II


13. Global Trispecific Antibody Market Dynamics
13.1 Favorable Market Parameters
13.2 Commercialization Challenges


14. Global Trispecific Antibody Market Future Perspective


15. Competitive Landscape
15.1 AbbVie
15.2 Affimed
15.3 Biotheus
15.4 Biontech
15.5 Genmab
15.6 GT Biopharma
15.7 Harpoon Therapeutics
15.8 MacroGenics
15.9 Numab
15.10 Sanofi
15.11 Sichuan Baili Pharmaceuticals



List of Figures

Figure 1-1: Structure of Trispecific Antibody

Figure 2-1: Trispecific Antibody – Mechanism of Action

Figure 3-1: Specificity of Monoclonal vs. Trispecific Antibody
Figure 3-2: Advantages of Trispecific Antibodies over Monoclonal Antibodies
Figure 3-3: Specificity of Bispecific vs. Trispecific Antibody
Figure 3-4: Binding Properties of Trispecific Antibody vs. CAR T Cell
Figure 3-5: Limitations of Peptide Drugs over Trispecific Antibodies
Figure 3-6: Limitations of Conventional Cancer Therapies over Trispecific Antibodies

Figure 4-1: Potential Therapeutic Targets for Trispecific Antibodies in Cancer

Figure 6-1: Trispecific Antibody Against HIV

Figure 8-1: Global – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
Figure 8-2: Global – Number of Cancer Deaths (Million), 2020, 2025 & 2030
Figure 8-3: Global – Trispecific Antibody Market Future Opportunity (US$ Million), 2024 - 2028
Figure 8-4: US – Trispecific Antibody Market Future Opportunity (US$ Million), 2024 - 2028
Figure 8-5: Global – Trispecific Antibody Market Estimation by Region (US$ Million), 2028
Figure 8-6: Global – Trispecific Antibody Market Estimation by Region (%), 2028
Figure 8-7: Global – Trispecific Antibody Market Estimation by Indication (US$ Million), 2028
Figure 8-8: Global – Trispecific Antibody Market Estimation by Indication (US$ Million), 2028
Figure 8-9: Global – Monoclonal Antibodies Market Opportunity (US$ Million), 2021 - 2028
Figure 8-10: Global – Trispecific Antibodies Market Opportunity by 0.5% of the Monoclonal Antibodies Market (US$ Million), 2024 - 2028

Figure 8-11: Global – Trispecific Antibodies Market Opportunity by 1% of the Monoclonal Antibodies Market (US$ Million), 2024 - 2028
Figure 8-12: Global – Trispecific Antibodies Market Opportunity by 1.5% of the Monoclonal Antibodies Market (US$ Million), 2024 - 2028
Figure 8-13: Global – Trispecific Antibodies Market Opportunity by 2% of the Monoclonal Antibodies Market (US$ Million), 2024 - 2028

Figure 9-1: GTB3550 – Initiation & Completion Year of Phase-I/II Clinical Trial
Figure 9-2: NM211480 – Initiation & Completion Year of Phase-I/II Clinical Trial
Figure 9-3: SAR443216 – Initiation & Completion Year of Phase-I/II Clinical Trial

Figure 10-1: Global - HPN217 Sales Forecast (US$ Million), 2024 - 2028
Figure 10-2: Global - HPN328 Sales Forecast (US$ Million), 2024 - 2028
Figure 10-3: Global - NM21 1480 Sales Forecast (US$ Million), 2024 - 2028
Figure 10-4: Global - SAR441236 Sales Forecast (US$ Million), 2024 - 2028

Figure 11-1: Global – Number of Trispecific Antibody Related Clinical Trials by Phase, November’2021
Figure 11-2: Global – Trispecific Antibody Related Clinical Trials by Phase (%), November’2021
Figure 11-3: Global – Number of Trispecific Antibodies Related Clinical Trials by Development Status, November’2021
Figure 11-4: Global – Breyanzi Related Clinical Trials by Development Status (%), November’2021
Figure 11-5: Global – Number of Trispecific Antibody Related Clinical Trials by Region, November’2021
Figure 11-6: Global – Number of Trispecific Antibodies Related Clinical Trials by Indication, November’2021
Figure 11-7: Global – Breyanzi Related Clinical Trials by Indication (%), November’2021

Figure 12-1: Global – Number of Trispecific Antibodies in Clinical Trials by Companies (%), November’2021
Figure 12-2: Global – Number of Trispecific Antibodies in Clinical Trials by Biomarkers (%), November’2021

Figure 12-3: Global – Number of Trispecific Antibodies in Clinical Trials by Mechanism of Action (%), November’2021
Figure 12-4: Global – Number of Trispecific Antibodies in Clinical Trials by Country (%), November’2021
Figure 13-1: Global – Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 13-2: Global – Trispecific Antibody Market Favorable Parameters
Figure 13-3: Global – Trispecific Antibody Market Challenges
Figure 15-1: GT Biopharma – Clinical Pipeline